Login / Signup

Clinical impact of transient lymphopenia.

Luigi PetramalaCinzia MilitoFrancesca SarloAdriana ServelloFrancesco CircostaLuca MarinoGermano SardellaPiero TrapaniGiulio D'aguannoAntonino Cimo'Gioacchino GalardoClaudio Letizia
Published in: Clinical and experimental medicine (2024)
Transient or persistent immunosuppression is a known risk factor for morbidity and mortality in critically ill patients. Aim of the present study is to evaluate the lymphopenia in patients admitted to the Emergency Unit of AOU Policlinico Umberto I, to investigate its prevalence at admission and the persistence during hospitalization until discharge. Possible correlations were evaluated between lymphopenia, diagnosis of admission, comorbidities and chronic treatments. In this study, 240 patients (142 men; 98 female; mean age 75.1 ± 15.1) were enrolled. Patients were divided into two groups according to the lymphocytes count at hospital admission, namely "Group A" with lymphopenia and "Group B" with values in the normal range. Moreover, the patients in group A were distinguished in relation to the regression or persistence of the lymphopenia assessed at the time of hospital discharge (Group A1: persistence; Group A2: normalization). Prevalence of lymphopenia at admission was 57%; Group A showed higher mean age and percentage of patients over 65 years of age; and none differences were observed regarding gender. Prevalence of lymphopenia at admission was 57%; Group A showed higher mean age and percentage of patients over 65 years of age; no differences were observed regarding gender. All subsets of the lymphocytes (CD4 + , CD8 + , NK) were equally reduced. Persistent lymphopenia was found in 19% of patients. Lymphopenia should be valued at the time of hospital admission as a factor influencing the prognosis, the management and the treatment of these patients.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • emergency department
  • prognostic factors
  • peritoneal dialysis
  • healthcare
  • patient reported outcomes
  • cerebral ischemia
  • adverse drug